Open Access Open Access  Restricted Access Subscription or Fee Access

Appendix: Impact of the extended-release/long-acting opioid analgesics risk evaluation and mitigation strategy on prescribing practices - Appendix

Matthew H. Secrest, MSc, Syd Phillips, MPH, M. Soledad Cepeda, MD, PhD, David M. Kern, MS, PhD, Daina B. Esposito, MPH, PhD, Gregory P. Wedin, PharmD

Abstract


Objective: To assess the impact of extended-release (ER)/long-acting (LA) opioid prescriber training on prescribing behaviors.

Design: Retrospective cohort study.

Setting: Prescriber training was evaluated from June 1, 2013 through December 31, 2016. The full study period was 2 years longer, from June 1, 2012 through December 31, 2017, to include data for all prescribers’ 1-year pretraining and post-training periods.

Participants: 24,428 prescribers who wrote ER/LA opioid prescriptions for eligible patients, with a record of training from the partner continuing education provider between June 1, 2013 and December 31, 2016.

Intervention: ER/LA opioid prescriber training. Main outcome measures: Prescribing behaviors 1-year before (pretraining) and after (post-training) prescribers completed training, specifically the proportion of opioid-nontolerant patients receiving ER/LA opioids indicated for opioid-tolerant patients and for patients receiving ≥100 morphine equivalents dose daily, and the proportion of concomitant users of central nervous system depressant drugs.

Results: The differences in the proportion of opioid-nontolerant patients receiving ER/LA opioids indicated for opioid-tolerant patients and for patients receiving ≥100 morphine equivalents dose daily were –0.69 percent (95 percent confidence interval [CI]: –1.78 percent, 0.40 percent) and –0.23 percent (95 percent CI: –1.18 percent, 0.68 percent), respectively. The differences in the proportion of concomitant users of central nervous system depressant drugs were –0.94 percent (95 percent CI: –1.39 percent; –0.48 percent) for benzodiazepines, 0.06 percent (95 percent CI: –0.13 percent; 0.25 percent) for antipsychotics, –0.41 percent (95 percent CI: –0.69 percent; –0.13 percent) for hypnotics/sedatives, and 0.08 percent (95 percent CI: –0.40 percent; 0.57 percent) for muscle relaxants.

Conclusions: While prescribers showed some changes in prescribing behavior after completing training, training was not associated with clinically relevant changes in prescribing behaviors.


Keywords


continuing education; extended-release; long-acting; opioid; opioid abuse; risk evaluation and mitigation strategy

Full Text:

PDF

References


Guy JG, Zhang K, Bohm MK, et al.: Vital signs: Changes in opioid prescribing in the United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017; 66(26): 697-704.

Jones CM, Mack KA, Paulozzi LJ: Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013; 309(7): 657-659.

Okie S: A flood of opioids, a rising tide of deaths. N Engl J Med. 2010; 363(21): 1981-1985.

United States Food and Drug Administration: Risk evaluation and mitigation strategy (REMS) for opioid analgesics. Available at http://er-la-opioidrems.com/IwgUI/rems/home.action. Accessed July 25, 2018.

United States Food and Drug Administration: FDA takes important steps to encourage appropriate and rational prescribing of opioids through final approval of new safety measures governing the use of immediate-release opioid analgesic medications. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm620935.htm. Accessed January 17, 2019.

United States Food and Drug Administration: Introduction for the FDA blueprint for prescriber education for extended-release and long-acting opioid analgesics. Available at https://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM515636.pdf. Accessed July 25, 2018.

United States Food and Drug Administration: Prescriber letter #3: FDA-required REMS program for serious drug risks. Available at https://www.accessdata.fda.gov/drugsatfda_docs/rems/ERLA_2017-05-26_Prescriber_Letter_3.pdf. Accessed August 8, 2018.

Bucher Bartelson B, Le Lait MC, Green JL, et al.: Changes in misuse and abuse of prescription opioids following implementation of extended-release and long-acting opioid analgesic risk evaluation and mitigation strategy. Pharmacoepidemiol Drug Saf. 2017; 26(9): 1061-1070.

Cepeda MS, Coplan PM, Kopper NW, et al.: ER/LA opioid analgesics REMS: Overview of ongoing assessments of its progress and its impact on health outcomes. Pain Med. 2017; 18(1): 78-85.

Esposito D, Desai V, Cepeda MS, et al.: Incidence of opioid overdose and death among patients using ER/LA opioid analgesics before and after implementation of the class-wide REMS. Presented at: American Academy of Pain Medicine Annual Meeting, March 16-19, 2017, Orlando, FL.

Divino V, Cepeda MS, Coplan P, et al.: Assessing the impact of the extended-release/long-acting opioid analgesics risk evaluation and mitigation strategies on opioid prescription volume. J Opioid Manag. 2017; 13(3): 157-168.

Reifler LM, Droz D, Bailey JE, et al.: Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med. 2012; 13(3): 434-442.

Centers for Disease Control and Prevention: State prescription drug laws. Available at www.cdc.gov/drugoverdose/policy/laws.html. Accessed April 24, 2017.

Bureau of Justice Assistance: Program performance report, prescription drug monitoring program. Available at https://www.bja.gov/Publications/PDMP_PPR_Jan-Dec13.pdf. Accessed April 24, 2014.

Mercer Inc: State Medicaid interventions for preventing prescription drug abuse and overdose: A report for the national association of Medicaid directors. Available at http://medicaiddirectors.org/publications/state-medicaid-interventions-for-preventing-prescription-drug-abuse-and-overdose/. Accessed April 24, 2017.

United States Department of Health and Human Services: Prevention programs & tools. Available at https://www.hhs.gov/opioids/prevention/prevention-programs-tools/index.html. Accessed February 25, 2019.

Davis CS, Carr D: Physician continuing education to reduce opioid misuse, abuse, and overdose: Many opportunities, few requirements. Drug Alcohol Depend. 2016; 163: 100-107.

Accreditation Council for Continuing Medical Education: The ACCME accreditation requirements. Available at https://www.accme.org/sites/default/files/2019-01/626_20190125_Accreditation_Requirements_Document.pdf. Accessed March 25, 2019.

Olfson M, King M, Schoenbaum M: Benzodiazepine use in the United States. JAMA Psychiatry. 2015; 72(2): 136-142.

Olfson M, King M, Schoenbaum M: Treatment of young people with antipsychotic medications in the United States. JAMA Psychiatry. 2015; 72(9): 867-874.

King M, Essick C: The geography of antidepressant, antipsychotic, and stimulant utilization in the United States. Health Place. 2013; 20: 32-38.

Schumock GT, Stayner LT, Valuck RJ, et al.: Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: A nested case-control study. J Allergy Clin Immunol. 2012; 130(2): 368-375.

Greenland S, Rothman KJ, Lash TL: Introduction to stratified analysis. In Seigafuse S, Bierig L (eds.): Modern Epidemiology. Philadelphia, PA: Lippincott Williams & Wilkins, 2008: 258-282.

Balding D, Cressie N, Fitzmaurice G, et al. (eds.): Introduction to Categorical Data Analysis. Hoboken, NJ: John Wiley & Sons, Inc., 2018.

United States Census Bureau: Census regions and divisions of the United States. Available at http://www2.census.gov/geo/pdfs/maps-data/maps/reference/us_regdiv.pdf. Accessed February 26, 2019.

Heyward J, Olson L, Sharfstein JM, et al.: Evaluation of the extended-release/long-acting opioid prescribing risk evaluation and mitigation strategy program by the US food and drug administration: A review. JAMA Intern Med. 2020; 180(2): 301-309.

Dowell D, Haegerich TM, Chou R: CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016; 315(15): 1624-1645.

Alford DP, Zisblatt L, Ng P, et al.: SCOPE of pain: An evaluation of an opioid risk evaluation and mitigation strategy continuing education program. Pain Med. 2016; 17(1): 52-63.

Chatterjee P, Finnegan T, Grimes C, et al.: Interim analysis of practice changes following participation in online and live ER/LA opioid CME/CE programs from the CO*RE collaborative (P1. 221). Presented at: American Academy of Neurology, April 22-28, 2017, Boston, MA.

Cervero RM: Effectiveness of continuing medical education: Updated synthesis of systematic reviews. Available at https://www.accme.org/sites/default/files/652_20141104_Effectiveness_of_Continuing_Medical_Education_Cervero_and_Gaines.pdf. Accessed December 7, 2022.

Mansouri M, Lockyer J: A meta-analysis of continuing medical education effectiveness. J Contin Educ Health Prof. 2007; 27(1): 6-15.

Bloom BS: Effects of continuing medical education on improving physician clinical care and patient health: A review of systematic reviews. Int J Technol Assess Health Care. 2005; 21(3): 380-385.

Marinopoulos SS, Dorman T, Ratanawongsa N, et al.: Effectiveness of continuing medical education. Evid Rep Technol Assess (Full Rep). 2007; 149(1): 1-69.

Murad MH, Coto-Yglesias F, Varkey P, et al.: The effectiveness of self-directed learning in health professions education: A systematic review. Med Educ. 2010; 44(11): 1057-1068.

Duensing K, Twillman R, Ziegler S, et al.: An examination of state and federal opioid analgesic and continuing education policies: 2016–2018. JPR. 2020; 13: 2431-2442.




DOI: https://doi.org/10.5055/jom.2023.0764-Appendix

Refbacks

  • There are currently no refbacks.